Pharmaceutical intermediates
Crizotinib Intermediates
3 pharmaceutical intermediates for Crizotinib. Indication: Primary cutaneous anaplastic large cell lymphoma; Anaplastic large cell lymphoma; Non-small cell lung cancer.
About Crizotinib
- Originator
- Pfizer Inc
- Indication
- Primary cutaneous anaplastic large cell lymphoma; Anaplastic large cell lymphoma; Non-small cell lung cancer
- Approved Date
- 08/26/2011
- DS/DP
- 03/01/2025
Available intermediates
3 intermediates currently listed for Crizotinib. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| tert-Butyl 4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H- pyrazol-1-yl]piperidine-1-carboxylate | 877399-74-1 | / | / |
| [5-Bromo-3-[(1R)-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin -2- yl]amine | 877399-00-3 | / | / |
| 2-amino-5-bromopyridin-3-ol | 39903-01-0 | / | / |
Building toward Crizotinib?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →